Gadolinium chelates with weak binding to serum proteins: A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging

Investigative Radiology

Volumn 32, Issue 12, 1997, Pages 780-796

  Cavagna, Friedrich M ^a   Maggioni, Fabio ^a   Castelli, Paolo M ^a   Daprà, Massimo ^a   Imperatori, Luigi G ^a   Lorusso, Vito ^a   Jenkins, Bruce G ^b  

^a Bracco SpA   (Italy)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Blood relaxation, in vivo blood relaxation enhancement; Blood brain barrier disruption; Gadobenate dimeglumine; Protein binding

Indexed keywords

B 21326 7; BOVINE SERUM ALBUMIN; CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOLINIUM CHELATE; GADOLINIUM PENTETATE MEGLUMINE; GADOLINIUM TRIS(BENZYLOXYMETHYL)PENTETIC ACID; GADOTERIDOL; PLASMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN TUMOR; CATTLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; DRUG STRUCTURE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RABBIT; RAT;

EID: 0031452736     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199712000-00009     Document Type: Article

References (62)

1. Goldstein HA, Kashanian KF, Blumetti RF, Holyoak WL, Hugo FP Blumenfield RF. Safety assessment of gadopentetate dimeglumine in U.S. clinical trials. Radiology 1990; 174:17-23.
2. Sze G, Brant-Zawadzki M, Haughton VM, et al. Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Radiology 1991; 181:693-699.
3. Runge VM, Bradley WG, Brant-Zawadzki M, et al. Clinical safety and efficacy of gadoteridol: A study in 411 patients with suspected intracranial and spinal disease. Radiology 1991; 181:701-709.
4. Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990; 14:249-265.
5. Kucharczyk J, Roberts T, Moseley ME, Watson A. Contrast-enhanced perfusion-sensitive MR imaging in the diagnosis of cerebrovascular disorders. J Magn Reson Imaging 1993; 3:241-245.
6. Prince MR. Body MR angiography with gadolinium contrast agents. Magn Reson Imaging Clin North Am 1996;4:11-24.
7. Leung DA, McKinnon GC, Davis CP, Pfammatter T, Krestin GP, Debatin JF. Breath-hold, contrast-enhanced, three-dimensional MR angiography. Radiology 1996; 200:569-571.
8. Lauffer RB. Targeted relaxation enhancement agents for MRI. Magn Reson Med 1991; 22:339-342.
9. Cavagna FM, Maggioni F, Casatelli PM, et al. Binding of Gd-BOPTA/Dimeg to extravasated serum proteins enhances conspicuity of brain tumors in rats. In: Proceedings of The Society of Magnetic Resonance. San Francisco: 1994. Abstract.
10. Donhaue KM, Weisskoff RM, Parmelee RC, et al. Evaluation of tumor cellular fraction and interstitial albumin concentration using Gd-DTPA and a novel albumin-binding contrast agent. In: Proceedings of The Society of Magnetic Resonance. San Francisco: 1994. Abstract.
11. Caramia F, Huang Z, Hamberg LM, et al. Identification of peripheral areas of cerebral flow-volume mismatch in focal transient ischemia using susceptibility contrast dynamic MRI. In: Proceedings of The Society of Magnetic Resonance. San Francisco: 1994. Abstract.
12. Cavagna FM, Maggioni F, Castelli PM, et al. Contrast enhanced magnetization transfer MRI of rat brain tumors with Gd-BOPTA/ Dimeg and Gd-DTPA/Dimeg. In: Proceedings of The Society of Magnetic Resonance and The Society for Magnetic Resonance in Medicine and Biology. Nice, France: 1995.
13. Jenkins BG, Caramia F, Matthews RT, et al. Evaluation of blood brain barrier dynamics and protein extravasation in a model of focal energy impairment using MRS and Gd-BOPTA enhanced MRI. In: Proceedings of The International Society for Magnetic Resonance in Medicine. New York: 1996. Abstract.
14. Maggioni F, Castelli PM, Lanens D, Cavagna FM. Determination of tissue relaxivity of Gd-BOPTA/Dimeg in rat brain tumors by IR-snapshot flash (Abstr). In: Proceedings of The International Society for Magnetic Resonance in Medicine. New York: 1996. Abstract.
15. Yu KK, Saeed M, Wendland MF, Derugin N, Cavagna FM, Higgins CB. Real-time dynamics of an extravascular magnetic resonance contrast medium in acutely infarcted myocardium using inversion recovery and gradient-recalled echo-planar imaging. Invest Radiol 1992; 27:927-934.
16. Saeed M, Wendland MF, Sakuma H, et al. Coronary artery stenosis: Detection with contrast-enhanced MR imaging in dogs. Radiology 1995; 196:79-84.
17. Marzola P, Maggioni F, Vicinanza E, Daprà M, Cavagna FM. Evaluation of the hepatocyte-specific contrast agent gadobenate dimeglumine for MR imaging of acute hepatitis in a rat model. J Magn Reson Imaging 1996; 7:147-152.
18. Daprà M, Marzola P, Imperatori L, Lanens D, Cavagna FM. Comparison of myocardial enhancement in rats during bolus transit of Gd-BOPTA/Dimeg and Gd-DTPA/Dimeg. In: Proceedings of The International Society for Magnetic Resonance in Medicine. New York: 1996. Abstract.
19. Caramia F, Foley MT, Moore J, et al. Use of Gd-BOPTA/Dimeg in peripheral magnetic resonance angiography. In: Proceedings of The International Society for Magnetic Resonance in Medicine. New York: 1996. Abstract.
20. Runge VM, Wells JW, Williams NM. Hepatic abscesses: Magnetic resonance imaging findings using Gd-BOPTA. Invest Radiol 1996;31:781-788.
21. Uggeri F, Aime S, Anelli PL, et al. Novel contrast agents for magnetic resonance imaging. Synthesis and characterization of the ligand BOPTA and its Ln(III) complexes (Ln Gd, La, Lu). X-ray structure of disodium (TPS-9-145337286-C-S)-[4-Carboxy5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8, 11- triazatridecan-13-oato(5-)]gadolinate(2-) in a mixture with its enantiomer. Inorganic Chemistry 1995;34:633-642.
22. de Haën C, Gozzini L. Soluble-type hepatobiliary contrast agents for MR imaging. J Magn Reson Imaging 1993;3:179-186.
23. Cavagna FM, Marzola P, Daprà M, et al. Binding of gadobenate dimeglumine to proteins extravasated into interstial space enhances conspicuity of reperfused infarcts. Invest Radiol 1994; 29(suppl 2):S50-S57.
24. Cavagna FM, Tirone P, Felder E, de Haën C. Hepatobiliary contrast agents for magnetic resonance imaging. In: Ferrucci JT, Stark DD, eds. Liver imaging. Reading, MA: Andover Medical Publishers, 1990:384-393.
25. Davies A, de Haën C. Gadobenic acid dimeglumine salt. Drugs of the Future 1991; 16(11):1001-1003.
26. Vittadini G, Felder E, Musu C, Tirone P. Preclinical profile of Gd-BOPTA: A liver-specific MRI contrast agent. Invest Radiol 1990; 25:S59-S60.
27. Vittadini G, Felder E, Tirone P, Lorusso V. B 19036, a potential new hepatobiliary contrast agent for MR proton imaging. Invest Radiol 1988; 23(suppl):246-248.
28. Rosati G, Pirovano G, Spinazzi A. Interim results of Phase II clinical testing of gadobenate dimeglumine. Invest Radiol 1994; 29(suppl):S183-S185.
29. Vogl TJ, Pegios W, McMahon C, et al. Gadobenate dimeglumine: A new contrast agent for MR imaging: Preliminary evaluation in healthy volunteers. AJR 1992; 158(4):887-892.
30. Pirovano G, Lorusso V, Tirone P, Rosati G. Tolerance and phamacokinetic evaluation of Gd-BOPTA/Dimeg in high doses in healthy volunteers. J Magn Reson Imaging 1993; 3(P):155.
31. 1, T2, and chemical-shift imaging. Magn Reson Med 1992; 13:77-89.
32. 1 values by SNAP-SHOT-FLASH NMR imaging. J Magn Reson 1992;96:608-612.
33. 1 maps by K-space reduced snapshot-FLASH MRI. J Comput Assist Tomogr 1992; 16(2):327-332.
34. 19F-MRI. Magn Reson Med 1995; 34(5):738-745.
35. Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 1993;61:1191-1206.
36. Jenkins BG, Brouillet E, Chen YCI, et al. Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J Cereb Blood Flow Metab 1996; 16:450-461.
37. Lauffer RB. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: Theory and design. Chem Rev 1987; 87:901-927.
38. Kirsch JE. Basic principles of magnetic resonance contrast agents. Topics Magn Reson Imaging 1991; 3(2): 1-18.
39. 1 of normal and reperfused infarcted myocardium after Gd-BOPTA versus Gd-DTPA on inversion recovery EPI. Magn Reson Med 1997; 37:448-456.
40. Mayr NA, Yuh WTC, Muhonen MG, et al. Cost-effectiveness of high-dose MR contrast studies in the evaluation of brain metastases. AJNR Am J Neuroradiol 1994; 15:1053-1061.
41. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol 1978; 19:579-592.
42. Russell DS, Rubenstein LJ. Pathology of tumours of the nervous system, ed. 5. Baltimore: Williams & Wilkins, 1989:809-854.
43. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322:494-500.
44. Posner JB. Diagnosis and treatment of metastases to the brain. Clin Bull 1974;4:47-57.
45. Moseley ME, Wendland MF, Kucharczyk J. Magnetic resonance imaging of diffusion and perfusion. Topics Magn Reson Imaging 1991;3(3):50-67.
46. Pierpaoli C, Righini A, Linfante I, Tao-Cheng JH, Alger JR, Di Chiro G. Histopathologic correlates of abnormal water diffusion in cerebral ischemia: Diffusion-weighted MR imaging and light and electron microscopic study. Radiology 1993; 189:439-448.
47. Yuh WTC, Fisher DJ, Engelken JD, et al. MR evaluation of CNS tumors: Dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 1991; 180:485-491.
48. Yuh WTC, Fisher DJ, Runge VM, et al. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases. Am J Neuroradiol 1994; 15:1037-1051.
49. Runge VM, Kirsch JE, Wells JW, Dunworth JN, Woolfolk CE. Visualization of blood-brain barrier disruption on MR images of cats with acute cerebral infarction: Value of administering a high dose of contrast material. AJR 1994; 162:431-435.
50. 1H magnetization transfer imaging in vivo. Magn Reson Med 1991; 17:304-314.
51. Wolff SD, Balaban RS. Magnetization transfer imaging: Practical aspects and clinical applications. Radiology 1994; 192:593-599.
52. Henkelman RM, Huang X, Xiang QS, Stanisz GJ, Swanson SD, Bronskill MJ. Quantitative interpretation of magnetization transfer. Magn Reson Med 1993;29:759-766.
53. Tanttu JI, Sepponen RE, Lipton MJ, Kuusela T. Synergistic enhancement of MRI with Gd-DTPA and magnetization transfer. J Comput Assist Tomogr 1992; 16(1):19-24.
54. Mathews VP, King JC, Elster AD, Hamilton CA. Cerebral infarction: Effects of dose and magnetization transfer saturation at gadolinium-enhanced MR imaging. Radiology 1994; 190:547-552.
55. Elster AD, King JC, Mathews VP, Hamilton CA. Cranial tissues: Appearance at gadolinium-enhanced and nonenhanced MR imaging with magnetization transfer contrast. Radiology 1994; 190:541-546.
56. Hossmann KA, Hürter T, Oschlies U. The effect of dexamethasone on serum protein extravasation and edema development in experimental brain tumor of cat. Acta Neuropathol 1983; 60:223-231.
57. Hossmann KA. Hemodynamic and metabolic disturbances in experimental peritumoral edema. In: Johansson BB, Owman C, Widner H. eds. Pathophysiology of the blood-brain barrier. New York: Elsevier Science Publishers, 1990:369-380.
58. Gullino PM, Clark SH, Grantham FH. The interstial fluid of solid tumors. Cancer Res 1964; 24(5):780-798.
59. Els T, Bockhorst K, Hoehn-Berlage M. NMR contrast enhancement of brain tumours: Comparison of the blood brain barrier tracer GdDTPA and tumour-selective contrast agent MnTPPS. MAGMA 1993;1:126-133.
60. Baxter LT, Rakesh KJ. Transport of fluid and macromolecules in tumors: II. Role of heterogeneous perfusion and lymphatics. Microvasc Res 1990;40:246-263.
61. Goldacre RJ, Sylven B. On the access of blood-borne dyes to various tumour regions. Br J Cancer 1962:306-322.
62. Lauffer RB, Parmelee DJ, Oullet HS, et al. MS-325: A small-molecule vascular imaging agent for magnetic resonance imaging. Acad Radiol 1996; 3:S356-S358.